Model of multiple myeloma treatment with Dara (control, <i>u</i>), including an immune response (purple arrows) and drug resistance mechanisms via loss of CD38 expression.
<p>The cell populations are healthy marrow cells (<i>A</i>), CD38+ cancer and CD38− cancer , and all arrows represent movement of cells between populations or states. Three drug actions are included (green arrows): cell mortality and loss of CD38 expression in the CD38+ cancer cell...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , |
| Published: |
2025
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1851561258736680960 |
|---|---|
| author | James G. Lefevre (11303976) |
| author2 | Brodie A. J. Lawson (8771843) Pamela M. Burrage (16938568) Diane M. Donovan (22033185) Kevin Burrage (21168) |
| author2_role | author author author author |
| author_facet | James G. Lefevre (11303976) Brodie A. J. Lawson (8771843) Pamela M. Burrage (16938568) Diane M. Donovan (22033185) Kevin Burrage (21168) |
| author_role | author |
| dc.creator.none.fl_str_mv | James G. Lefevre (11303976) Brodie A. J. Lawson (8771843) Pamela M. Burrage (16938568) Diane M. Donovan (22033185) Kevin Burrage (21168) |
| dc.date.none.fl_str_mv | 2025-08-11T17:43:04Z |
| dc.identifier.none.fl_str_mv | 10.1371/journal.pcbi.1012225.g001 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/figure/Model_of_multiple_myeloma_treatment_with_Dara_control_i_u_i_including_an_immune_response_purple_arrows_and_drug_resistance_mechanisms_via_loss_of_CD38_expression_/29884875 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biophysics Biochemistry Medicine Genetics Pharmacology Biotechnology Cancer Hematology Infectious Diseases Biological Sciences not elsewhere classified target drug effects plasma cell cancer monoclonal antibody daratumumab target drug effect healthy cells due cd38 expression switches optimal treatment regime drug resistance mechanisms healthy cells drug action cd38 expression cancer cells optimal treatment added mechanisms optimal control myeloma cells leading treatment express cd38 daratumumab treatment cd38 receptor proposed mechanism ode model lower fitness indirect effect identified within highly overexpressed general increase direct effect bone marrow |
| dc.title.none.fl_str_mv | Model of multiple myeloma treatment with Dara (control, <i>u</i>), including an immune response (purple arrows) and drug resistance mechanisms via loss of CD38 expression. |
| dc.type.none.fl_str_mv | Image Figure info:eu-repo/semantics/publishedVersion image |
| description | <p>The cell populations are healthy marrow cells (<i>A</i>), CD38+ cancer and CD38− cancer , and all arrows represent movement of cells between populations or states. Three drug actions are included (green arrows): cell mortality and loss of CD38 expression in the CD38+ cancer cells, and off-target cell mortality in healthy cells within the compartment.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_ead751d6fc3a652176b51bfbcbb64fb7 |
| identifier_str_mv | 10.1371/journal.pcbi.1012225.g001 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/29884875 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Model of multiple myeloma treatment with Dara (control, <i>u</i>), including an immune response (purple arrows) and drug resistance mechanisms via loss of CD38 expression.James G. Lefevre (11303976)Brodie A. J. Lawson (8771843)Pamela M. Burrage (16938568)Diane M. Donovan (22033185)Kevin Burrage (21168)BiophysicsBiochemistryMedicineGeneticsPharmacologyBiotechnologyCancerHematologyInfectious DiseasesBiological Sciences not elsewhere classifiedtarget drug effectsplasma cell cancermonoclonal antibody daratumumabtarget drug effecthealthy cells duecd38 expression switchesoptimal treatment regimedrug resistance mechanismshealthy cellsdrug actioncd38 expressioncancer cellsoptimal treatmentadded mechanismsoptimal controlmyeloma cellsleading treatmentexpress cd38daratumumab treatmentcd38 receptorproposed mechanismode modellower fitnessindirect effectidentified withinhighly overexpressedgeneral increasedirect effectbone marrow<p>The cell populations are healthy marrow cells (<i>A</i>), CD38+ cancer and CD38− cancer , and all arrows represent movement of cells between populations or states. Three drug actions are included (green arrows): cell mortality and loss of CD38 expression in the CD38+ cancer cells, and off-target cell mortality in healthy cells within the compartment.</p>2025-08-11T17:43:04ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1371/journal.pcbi.1012225.g001https://figshare.com/articles/figure/Model_of_multiple_myeloma_treatment_with_Dara_control_i_u_i_including_an_immune_response_purple_arrows_and_drug_resistance_mechanisms_via_loss_of_CD38_expression_/29884875CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/298848752025-08-11T17:43:04Z |
| spellingShingle | Model of multiple myeloma treatment with Dara (control, <i>u</i>), including an immune response (purple arrows) and drug resistance mechanisms via loss of CD38 expression. James G. Lefevre (11303976) Biophysics Biochemistry Medicine Genetics Pharmacology Biotechnology Cancer Hematology Infectious Diseases Biological Sciences not elsewhere classified target drug effects plasma cell cancer monoclonal antibody daratumumab target drug effect healthy cells due cd38 expression switches optimal treatment regime drug resistance mechanisms healthy cells drug action cd38 expression cancer cells optimal treatment added mechanisms optimal control myeloma cells leading treatment express cd38 daratumumab treatment cd38 receptor proposed mechanism ode model lower fitness indirect effect identified within highly overexpressed general increase direct effect bone marrow |
| status_str | publishedVersion |
| title | Model of multiple myeloma treatment with Dara (control, <i>u</i>), including an immune response (purple arrows) and drug resistance mechanisms via loss of CD38 expression. |
| title_full | Model of multiple myeloma treatment with Dara (control, <i>u</i>), including an immune response (purple arrows) and drug resistance mechanisms via loss of CD38 expression. |
| title_fullStr | Model of multiple myeloma treatment with Dara (control, <i>u</i>), including an immune response (purple arrows) and drug resistance mechanisms via loss of CD38 expression. |
| title_full_unstemmed | Model of multiple myeloma treatment with Dara (control, <i>u</i>), including an immune response (purple arrows) and drug resistance mechanisms via loss of CD38 expression. |
| title_short | Model of multiple myeloma treatment with Dara (control, <i>u</i>), including an immune response (purple arrows) and drug resistance mechanisms via loss of CD38 expression. |
| title_sort | Model of multiple myeloma treatment with Dara (control, <i>u</i>), including an immune response (purple arrows) and drug resistance mechanisms via loss of CD38 expression. |
| topic | Biophysics Biochemistry Medicine Genetics Pharmacology Biotechnology Cancer Hematology Infectious Diseases Biological Sciences not elsewhere classified target drug effects plasma cell cancer monoclonal antibody daratumumab target drug effect healthy cells due cd38 expression switches optimal treatment regime drug resistance mechanisms healthy cells drug action cd38 expression cancer cells optimal treatment added mechanisms optimal control myeloma cells leading treatment express cd38 daratumumab treatment cd38 receptor proposed mechanism ode model lower fitness indirect effect identified within highly overexpressed general increase direct effect bone marrow |